DXCM
DexCom, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website dexcom.com
- Employees(FY) 7500
- ISIN US2521311074
Performance
-0.74%
1W
+11.6%
1M
+21.24%
3M
+24.89%
6M
+11.93%
YTD
-28.27%
1Y
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Technical Analysis of DXCM 2025-02-03
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-01-14 08:11
- 2025-01-14 07:38
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue(Medical Device Network)
- 2025-01-14 06:11
- 2025-01-13 08:36
- 2025-01-13 08:23
- 2025-01-13 07:30
- 2025-01-12 18:30
- 2025-01-09 08:37
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.(Investor's Business Daily)
- 2025-01-09 06:12
- 2025-01-08 16:35
- 2025-01-08 08:30
- 2025-01-07 19:30
- 2025-01-07 19:00
DXCM: Raising target price to $63.00(Argus Research)
- 2025-01-07 19:00
TRUP: Lowering target price to $50.00(Argus Research)
- 2025-01-07 08:30
- 2025-01-06 06:00
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher(Simply Wall St.)
- 2025-01-04 07:45
- 2025-01-02 06:26
Abbott, Dexcom settle glucose monitor patent lawsuits(MedTech Dive)
- 2025-01-01 09:37
- 2024-12-31 06:00
DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy(Simply Wall St.)
- 2024-12-30 19:00
DXCM: Lowering target price to $51.00(Argus Research)
- 2024-12-30 19:00
DXCM: Lowering target price to $62.00(Argus Research)
- 2024-12-27 07:00
At US$80.57, Is DexCom, Inc. (NASDAQ:DXCM) Worth Looking At Closely?(Simply Wall St.)
- 2024-12-27 05:11
- 2024-12-25 10:15
- 2024-12-25 05:30
- 2024-12-24 05:10
- 2024-12-23 19:00
DXCM: Lowering target price to $52.00(Argus Research)
- 2024-12-23 19:00
DXCM: Raising target price to $64.00(Argus Research)
- 2024-12-23 16:56
DexCom, Abbott Agree to Settlement in Patent Litigation(The Wall Street Journal)
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.